Accelerate Diagnostics Company Insiders
| AXDX Stock | USD 1.35 0.03 2.27% |
Accelerate Diagnostics employs about 134 people. The company is managed by 14 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 9.57 employees per reported executive. Break down of Accelerate Diagnostics' management performance can provide insight into the company performance.
| Ron Price President Senior Vice President Head - Commercial Operations |
Accelerate |
Accelerate Diagnostics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7585) % which means that it has lost $0.7585 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.Accelerate Diagnostics Workforce Comparison
Accelerate Diagnostics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 26,814. Accelerate Diagnostics adds roughly 134 in number of employees claiming only tiny portion of equities under Health Care industry.
Accelerate Diagnostics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Accelerate Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Accelerate Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Accelerate Diagnostics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Accelerate Diagnostics Notable Stakeholders
An Accelerate Diagnostics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Accelerate Diagnostics often face trade-offs trying to please all of them. Accelerate Diagnostics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Accelerate Diagnostics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jack Phillips | President CEO | Profile | |
| Ron Price | Senior Vice President Head - Commercial Operations | Profile | |
| Steve Reichling | CFO, Chief Accounting Officer and Secretary | Profile | |
| David Patience | Principal CFO | Profile | |
| Lawrence Mertz | Chief Officer | Profile | |
| Michael Bridge | Gen VP | Profile | |
| Laura Costa | VP Support | Profile | |
| Rita Boukamel | Senior EMEA | Profile | |
| Maya Gowri | Senior Operations | Profile | |
| Cherif Bousselham | VP EMEA | Profile | |
| Chris Thode | Senior Commercial | Profile | |
| Gretchen Strohminger | Senior Culture | Profile | |
| John Meduri | Chief Officer | Profile | |
| Laura Pierson | Investor Officer | Profile |
About Accelerate Diagnostics Management Performance
The success or failure of an entity such as Accelerate Diagnostics often depends on how effective the management is. Accelerate Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Accelerate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Accelerate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people.
Please note, the imprecision that can be found in Accelerate Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Accelerate Diagnostics. Check Accelerate Diagnostics' Beneish M Score to see the likelihood of Accelerate Diagnostics' management manipulating its earnings.
Accelerate Diagnostics Workforce Analysis
Traditionally, organizations such as Accelerate Diagnostics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Accelerate Diagnostics within its industry.Accelerate Diagnostics Manpower Efficiency
Return on Accelerate Diagnostics Manpower
| Revenue Per Employee | 90K | |
| Revenue Per Executive | 861.4K | |
| Net Loss Per Employee | 459.8K | |
| Net Loss Per Executive | 4.4M | |
| Working Capital Per Employee | 92.8K | |
| Working Capital Per Executive | 888K |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.